FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to rheumatology and ophthalmology, and can be used for diagnosing degenerative corneal changes in patients suffering rheumatoid arthritis depending on the determined rheumatoid factor. With indices less than 14 IU/ml, diagnosed absence perilimbal degenerative changes of a cornea in eye fissure projection with the outer and inner sides, and at rates greater than or equal to 14 IU/ml – presence of corneal changes.
EFFECT: method enables predicting degenerative corneal changes in patients suffering rheumatoid arthritis, without special ophthalmic examination – biomicroscopy, by determining the rheumo factor by standard technique, that allows diagnosing presence or absence of degenerative perilimbal changes of a cornea in a projection of an eye fissure.
1 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSTIC OF PATHOLOGY OF TOTAL TEAR SECRETION IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2017 |
|
RU2677192C1 |
| METHOD FOR DIAGNOSING THE NEED TO PRESCRIBE GLUCOCORTICOIDS SYSTEMICALLY IN PATIENTS WITH RHEUMATIC DISEASE | 2021 |
|
RU2760260C1 |
| METHOD FOR PRECLINICAL DIAGNOSTICS OF JUVENILE RHEUMATOID ARTHRITIS | 2000 |
|
RU2195856C2 |
| METHOD FOR COMPLEX TREATMENT OF HEMODYNAMIC DISORDERS OF BULBAR CONJUNCTIVA OF PATIENTS WITH COVID-19 ASSOCIATED PNEUMONIA | 2021 |
|
RU2747408C1 |
| METHOD FOR TREATING PATHOLOGY OF TOTAL TEAR SECRETION IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2017 |
|
RU2677190C1 |
| METHOD OF TREATING PERIPHERAL ULCERATIVE KERATITIS ACCOMPANYING SJOGREN'S SYNDROME ASSOCIATED WITH RHEUMATOID ARTHRITIS | 2015 |
|
RU2585611C1 |
| METHOD OF PREDICTION SEVERE FORM OF DRY EYE SYNDROME IN SJÖGREN SYNDROME ASSOCIATED WITH RHEUMATOID ARTHRITIS | 2018 |
|
RU2679799C1 |
| METHOD OF DIAGNOSING CHRONIC VASCULAR PATHOLOGY OF OPTIC NERVE | 2008 |
|
RU2374981C1 |
| DIAGNOSTIC TECHNIQUE FOR RHEUMATOID ARTHRITIS | 2014 |
|
RU2554755C1 |
| METHOD FOR THE ETIOPATHOGENETIC TREATMENT OF PARAVASAL DISORDERS OF BULBAR CONJUNCTIVA IN PATIENTS WITH COVID-19 ASSOCIATED PNEUMONIA | 2021 |
|
RU2760297C1 |
